Health Care & Life Sciences » Pharmaceuticals | Adamis Pharmaceuticals Corp.

Adamis Pharmaceuticals Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
6,474.00
13,073.30
15,086.60
Cost of Goods Sold (COGS) incl. D&A
-
1,184.50
990.30
7,388.30
10,483.50
12,896.90
Gross Income
-
1,184.50
990.30
914.30
2,589.70
2,189.70
SG&A Expense
3,217.60
9,617.80
12,860.10
24,290.10
27,282.50
42,542
EBIT
3,217.60
10,802.30
13,850.40
25,204.40
24,692.70
40,352.20
Unusual Expense
1,513.20
1,317.70
278.40
1,397.50
1,056.60
10.50
Interest Expense
2,334.00
301.70
-
214.40
231.30
157.80
Pretax Income
7,064.80
12,421.80
13,572.00
24,012.00
25,878.40
40,275.10
Income Tax
-
-
-
4,574.80
339.40
1,268.30
Consolidated Net Income
7,064.80
12,421.80
13,572.00
19,437.30
25,539.00
39,006.80
Net Income
7,064.80
12,421.80
13,572.00
19,437.30
25,539.00
39,006.80
Net Income After Extraordinaries
6,934.80
12,421.80
13,572.00
19,437.30
25,539.00
39,006.80
Net Income Available to Common
7,194.80
12,421.80
13,572.00
20,811.50
25,539.00
39,006.80
EPS (Basic)
1.19
1.18
1.03
1.19
0.90
1
Basic Shares Outstanding
5,858.80
10,526.60
13,275.80
17,500.80
28,349.40
39,085.50
EPS (Diluted)
1.23
1.18
1.03
1.19
0.90
1
Diluted Shares Outstanding
5,858.80
10,526.60
13,436.70
17,500.80
28,349.40
39,085.50
EBITDA
3,217.60
9,617.80
12,860.10
22,669.80
21,629.20
37,253.30
Non-Operating Interest Income
-
-
-
9.30
102.20
245.40
Preferred Dividends
-
-
-
1,374.20
-
-

About Adamis Pharmaceuticals

View Profile
Address
11682 El Camino Real
San Diego California 92130
United States
Employees -
Website http://www.adamispharmaceuticals.com
Updated 07/08/2019
Adamis Pharmaceuticals Corp. is a biopharmaceutical company which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. . Its activities include the combination of pharmaceuticals and biotechnology to produce medicines for patients, and physicians.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.